1. Yamaguchi Y, Noriyuki N, Kaburaki J, et al. Excesive exposure to aninic surfaces maitains autoantiboy response to B2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007;110:4312-18

2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4:205-306

3. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J. 1983;287:1088-9.

4. Alijotas-Reig J. Towards the comprehension of heterogeneity of clinical manifestations related to antiphospholipid antibodies. Med Clin (Barc) 2005;125:187-89

5. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic non-autoimmune women with unexplained recurrent primary early fetal loss. The Nimes Obstericians and Haematologists study-NOHA. Thromb Haemost 2000;84:228-236

6. Asherson RA, Cervera R, Shepshelovich D, et al. Nonthrombotic manifestations of the antiphospholipid syndrome: away from thrombosis? J Rheumatol 2006;33:1038-1044

7. Out HJ, Kooijman CD, Bruinse HW, et al Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynaecol repord Biol 1991;195:211-20

8. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nature Med 2004;10:1222-26

9. Alijotas-Reig J, Izquiedo M, Serra B, et al. Antiphospholipid autoantibodies, complement levels, hypergammaglobulinemia and spontaneous intrauterine haematomas in pregnant women. Am J Reprod Immunol 2003;49:1-6

10. Carbone J, Sarmiento E, Rodriguez-Molina J, et al.. Hipocomplementemia C3 y C4 en el síndrome antifosfolípido obstétrico. Rev Clin Esp 2008;208:168-171

11. Salmon JE, Girardi G. Antiphospholipid syndrome revisited: a disorder initiated by inflammation. Lupus 2007;16 (abst suppl):1-2

12. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nature Med 2004;10:1222-26

13. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005;174:1222-1226

14. Chu AJ. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct 2006;24:173-92

15. Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006;203:2165-75

16. Case Records (case 8-2009). N Engl J Med 2009;360:1126-37

16. Boffa M-C, Boinot C, de Carolis S, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome (APS). Data from a multicentric propstective European women cohort. Thromb Haemost 2009 [in press]

17. Alijotas-Reig J, Vilardell-Tarrés M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?. Obstet Gynecol Surv (in press. It will be published in January/February 2010).


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: